Combined Tyrosine Kinase Inhibitors and Chemotherapy Based on Minimal Residual Disease in Children With Ph⁺ Acute Lymphoblastic Leukemia: A Phase 2 Single-Arm Trial, JCCG ALL-Ph13.

Q: What does this research mean for the field?

The combination of tyrosine kinase inhibitors and chemotherapy in children with Ph+ acute lymphoblastic leukemia maintains comparable outcomes while significantly reducing the need for hematopoietic stem cell transplantation. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

Atsushi Sato; Yuichi Kodama; Hirohide Kawasaki; Kentaro Ohki; Koichi Oshima; Takao Deguchi; Yoshiko Hashii; Y. Iijima-Yamashita; Sachiko Yonezawa; Chiyo K. Imamura; Haruko Shima; Hirotoshi Sakaguchi; Koji Kato; M. Kato; Hidefumi Hiramatsu; Etsuro Ito; Masaki Yamamoto; Akiko Inoue; Kimiyoshi Sakaguchi; Yoshiyuki Kosaka; Daisuke Hasegawa; Nobutaka Kiyokawa; Akiko Kada; Akihiro Hirakawa; Atsushi Manabe; Keizo Horibe; Hiroyuki Shimada

doi:10.1002/1545-5017.70173

Key Points

To evaluate the efficacy of combining tyrosine kinase inhibitors with chemotherapy in treating children with Ph+ acute lymphoblastic leukemia.
Conducted a phase 2 single-arm trial
Focused on children with Ph+ ALL
Reduced intensity of hematopoietic stem cell transplantation (HSCT)
Evaluated outcomes based on minimal residual disease
Achieved comparable outcomes to previous studies
Significant reduction in HSCT
Indicated a need for optimizing TKI administration duration for better long-term event-free survival (EFS)

Implication

Phase 2 trial analyzes treatment outcomes in children with Ph+ acute lymphoblastic leukemia, suggesting further optimization is needed.

Abstract

Compared with Ph+ALL04, HSCT was substantially reduced in ALL-Ph13 while maintaining comparable outcomes. Further optimization of treatment, particularly the duration of TKI administration, is needed to maintain long-term EFS.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Sato et al. (2026) studied this question.

synapsesocial.com/papers/69a13591ed1d949a99abf8f7 https://doi.org/10.1002/1545-5017.70173

View at Publisher

Ask AI

Bookmark

Share

Combined Tyrosine Kinase Inhibitors and Chemotherapy Based on Minimal Residual Disease in Children With Ph⁺ Acute Lymphoblastic Leukemia: A Phase 2 Single-Arm Trial, JCCG ALL-Ph13.

Key Points

Implication

Abstract

Discussion

Cite This Study

Combined Tyrosine Kinase Inhibitors and Chemotherapy Based on Minimal Residual Disease in Children With Ph⁺ Acute Lymphoblastic Leukemia: A Phase 2 Single-Arm Trial, JCCG ALL-Ph13.

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

Keep reading

More related papers